Bupropion SR for smoking cessation in smokers with cardiovascular disease: A multicentre, randomised study

Serena Tonstad, C. Farsang, G. Klaene, K. Lewis, A. Manolis, A. P. Perruchoud, C. Silagy, P. I. Van Spiegel, C. Astbury, A. Hider, R. Sweet

Research output: Contribution to journalArticle

196 Citations (Scopus)

Abstract

Aim: To investigate the safety and efficacy of bupropion sustained release (bupropion SR) in promoting abstinence from smoking in subjects with cardiovascular disease (CVD). Methods: Six hundred twenty-nine subjects with CVD who smoked ≥10 cigarettes/day were randomised in a double-blind, multicentre study to receive bupropion SR (150 mg twice daily) or placebo for 7 weeks, with a follow-up of 52 weeks. Primary efficacy endpoint: continuous abstinence from smoking from weeks 4 to 7. Secondary endpoints: continuous abstinence (weeks 4-12, 4-26 and 4-52) and weekly point prevalence abstinence. All participants received brief motivational support. Safety was evaluated throughout the study. Results: Continuous smoking abstinence rates from weeks 4 to 7 were significantly higher in subjects receiving bupropion SR compared with placebo (43 vs. 19%, odds ratio [OR]=3.27, 95% confidence interval [CI] 2.24-4.84; P<0.001). Continuous abstinence rates from weeks 4 to 26 and 4 to 52 continued to be more than double for bupropion SR compared with placebo (27 vs. 11%; 22 vs. 9%, P<0.001). Weekly point prevalence abstinence was significantly higher for participants who received bupropion SR compared with placebo at weeks 3, 7, 26 and 52 (P<0.001). In both groups, there were no clinically significant changes in blood pressure and heart rate throughout the treatment phase. Overall, 6% of the participants (n=36) discontinued study medication due to an adverse event (bupropion SR, n=17; placebo, n=19). Conclusions: After 7 weeks of bupropion SR treatment, more than twice as many smokers with CVD had quit smoking at 1 year compared with placebo. The safety profile of bupropion SR was similar to that previously observed in general smoking populations.

Original languageEnglish
Pages (from-to)946-955
Number of pages10
JournalEuropean heart journal
Volume24
Issue number10
DOIs
Publication statusPublished - May 2003

Keywords

  • Bupropion sustained release
  • Cardiovascular disease
  • Smoking cessation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Bupropion SR for smoking cessation in smokers with cardiovascular disease: A multicentre, randomised study'. Together they form a unique fingerprint.

  • Cite this

    Tonstad, S., Farsang, C., Klaene, G., Lewis, K., Manolis, A., Perruchoud, A. P., Silagy, C., Van Spiegel, P. I., Astbury, C., Hider, A., & Sweet, R. (2003). Bupropion SR for smoking cessation in smokers with cardiovascular disease: A multicentre, randomised study. European heart journal, 24(10), 946-955. https://doi.org/10.1016/S0195-668X(03)00003-4